Treatment discontinuation and dosing information at 8-month follow-up
Efficacy cohort . | MBC-CML . | LBC-CML . |
---|---|---|
No. patients | 74 | 42 |
Still on treatment, no. (%) | 23 (31) | 5 (12) |
Discontinued study therapy, no. (%) | 51 (69) | 37 (88) |
Disease progression | 25 (34) | 22 (52) |
Study drug toxicity | 8 (11) | 1 (2) |
AE unrelated to study drug | 2 (3) | 0 (0) |
Death | 7 (9) | 6 (14) |
Noncompliance | 1 (1) | 0 (0) |
Deterioration without progression | 2 (3) | 3 (7) |
Other | 6 (8) | 5 (12) |
Median duration of dasatinib therapy, mo (range) | ||
Total treated population | 3.5 (0.03-12.0) | 2.8 (0.1-9.2) |
Population still on study | 9.2 (7.8-12.0) | 8.3 (7.6-9.2) |
Median of average daily dasatinib dose, mg/d | 137.0 | 140.0 |
Efficacy cohort . | MBC-CML . | LBC-CML . |
---|---|---|
No. patients | 74 | 42 |
Still on treatment, no. (%) | 23 (31) | 5 (12) |
Discontinued study therapy, no. (%) | 51 (69) | 37 (88) |
Disease progression | 25 (34) | 22 (52) |
Study drug toxicity | 8 (11) | 1 (2) |
AE unrelated to study drug | 2 (3) | 0 (0) |
Death | 7 (9) | 6 (14) |
Noncompliance | 1 (1) | 0 (0) |
Deterioration without progression | 2 (3) | 3 (7) |
Other | 6 (8) | 5 (12) |
Median duration of dasatinib therapy, mo (range) | ||
Total treated population | 3.5 (0.03-12.0) | 2.8 (0.1-9.2) |
Population still on study | 9.2 (7.8-12.0) | 8.3 (7.6-9.2) |
Median of average daily dasatinib dose, mg/d | 137.0 | 140.0 |